1.Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, Hunter DJ, Hennekens CH, Speizer FE. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. Ann Intern Med 1993;119:992-1000. Medline

2.Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch Intern Med 1994;154:169-75. Medline

3.Hermanson B, Omenn GS, Kronmal RA, Gersh BJ. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease. Results from the CASS registry. N Engl J Med 1988;319:1365-9. Medline

4.Jorenby DE, Leischow SJ, Nides MA et al. A controlled trial of sustained release bupropion, a nicotine patch or both for smoking cessation. N Engl J Med 1999;340:685-91. Medline

5.Blair SN, Kohl HW, Barlow CE, Paffenbarger RS, Gibbons LW, Macera CA. Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. JAMA 1995;273:1093-8. Medline

6.Hedblad B, Ogren M, Isacsson SO, Janzon L. Reduced cardiovascular mortality risk in male smokers who are physically active. Results from a 25-year follow-up of the prospective population study men born in 1914. Arch Intern Med 1997;157:893-9. Medline

7.Manson JE, Hu FB, Rich-Edwards JW et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999;341:650-658. Medline

8.Griffiths TL, Burr ML, Campbell IA et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000;355:362-8. Medline

9.Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, Andersson I, Bjurstam N, Fagerberg G, Frisell J, et al. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 1993;341:973-8. Medline>

9a Nystrom L Andersson I Bjurstam N et al. Long-term effects of mammography screeining : updated overview of the Swedish randomised trials. Lancet 2002;359:909-19.

10.Van Dijck JA, Verbeek AL, Beex LV, Hendriks JH, Holland R, Mravunac M, Straatman H, Werre JM. Breast-cancer mortality in a non-randomized trial on mammographic screening in women over age 65. Int J Cancer 1997;70(2):164-8. Medline>

11.16-year mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer. Lancet 1999 Jun 5;353:1909-14. Medline>

12.Wallin KL, Wiklund F, Angstrom T et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-8. Medline

13.ANDEM. Pratique des frottis cervicaux pour le dépistage du cancer du col. Recommandations et références médicales 1995;T2:9-24 Référence.

14.Quinn M et al. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. Br Med J 1999;318:904-8. Medline

15.Office fédéral de la santé publique. Groupe d'experts pour les questions liées à la vaccination. Plan de vaccination de routine, in OFSP, ed. Maladies infectieuses. Diagnostic et prévention. Berne OFSP 1998(5):4-5.

16.Bovier P, Gallachi-Bouvier M. Les vaccinations chez les adultes en Suisse: le point de vue des médecins de premier recours et de leurs patients. OFSP 316.98.6766 1999

17.Office fédéral de la santé publique. Communiqué de presse 21 décembre 1992.

18.John TJ. The final stages of the global eradication of polio. New Engl J Med 2000343. Medline

19.Groupe d'étude canadienne sur l'examen périodique. Guide canadien de médecine clinique préventive, Canadian Medical Association, Ottawa, septembre 1994. Référence

20.Dobson S, Scheifele D, Bell A. Assessment of a universal, school-based hepatitis B vaccination program. JAMA 1995 Oct 18;274(15):1209-13. Medline

21.Barquet N, Domingo P, Caylà JA. Vaccination against HBV in France. Lancet 1999;353:414. Medline

22.Hak E, van Essen GA, Buskens E, Stalman W, de Melker RA. Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands. J Epidemiol Community Health 1998;52:120-5. Medline>

23.Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M, Magnan S, Drake M. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995;333(14):889-93. Medline

24.Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331(12):778-84. Medline

25.Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123(7):518-27. Medline

26.Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999;281(10):908-13. Medline

27.Potter J, Stott DJ, Roberts MA, Elder AG, O'Donnell B, Knight PV, Carman WF. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997;175:1-6. Medline

28.Fine M, Smith M, Carson C et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994;154:2666-77. Medline

29.Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997;103(4):281-90. Medline

30.Ketterer JP, Rochat TH. Vaccin anti-pneumococcique. Med Hyg 1999;57:2329-33.

31.Nuorti JP, Butler JC, Farley MM et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000;342:681-9. Medline

32.Infections à pneumocoques invasifs en Suisse. Bulletin de l'Office fédéral de la Santé publique, 2000,20:381-5.

33.Advances in global measles control and elimination: summary of the 1997 international meeting. MMWR;1998;47(RR-11):1-23. Medline

34.Cutts FT. Revaccination against measles and rubella. BMJ 1996;312:589-590. Medline>

35.De Quadros CA, Hersh BS, Nogueira AC, Carrasco PA, da Silveira CM. Measles eradication: experience in the Americas. Bull World Health Organ. 1998;76(S2):47-52. Medline

36.Office fédéral suisse de la santé publique.

37.Measles Outbreak - Netherlands, April 1999-January 2000. MMWR 2000;49(14):299-303. Medline

38.Berger K, Ajani UA, Kase CS et al. Light-to-moderate alcohol consumption and risk of stroke among U.S. male physicians. N Engl J Med 1999;341:1557-64. Medline

39.Gaziano JM, Gaziano TA, Glynn RJ, Sesso HD, Ajani UA, Stampfer MJ, Manson JE, Hennekens CH, Buring JE. Light-to-moderate alcohol consumption and mortality in the Physicians' Health Study enrollment cohort. J Am Coll Cardiol 2000 Jan;35(1):96-105. Medline

40.Liu S, Stampfer MJ, Hu FB, Giovannucci E, Rimm E, Manson JE, Hennekens CH, Willett WC. Whole-grain consumption and risk of coronary heart disease: results from the Nurses' Health Study. Am J Clin Nutr 1999;70(3):412-9. Medline

41.Rimm EB, Ascherio A, Giovannucci E, Spiegelman D, Stampfer MJ, Willett WC. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA 1996 Feb 14;275(6):447-51. Medline

42.Alberts DS, Martinez ME, Roe DJ et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 2000 Apr 20;342(16):1156-62. Medline

43.Joshipura KJ, Ascherio A, Manson JE, Stampfer MJ, Rimm EB, Speizer FE, Hennekens CH, Spiegelman D, Willett WC. Fruit and vegetable intake in relation to risk of ischemic stroke. JAMA 1999;282(13):1233-9. Medline

44.Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960-8. Medline

45.De Lorgeril M, Salen P, Martin JL, Mamelle N. Effect of a mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. Insights into the cardioprotective effect of certain nutriments. J Am Coll Cardiol 1996;28(5):1103-8. Medline

46.Watts GF, Lewis B, Brunt JN, Lewis ES. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339(8793):563-9. Medline

47 .Ornish D, Brown SE, Scherwitz LW. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990;336(8708):129-33. Medline

48.Mayfield D, McLeod G, Hall P. The CAGE (ACME) questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry 1974;131:1121-3. Medline

49.Bush B, Shaw S, Cleary P, Delbanco TL, Aronson MD. Screening for alcohol abuse using CAGE (ACME) questionnaire. Am J Med 1987;82:231-5. Medline

50.Bradley KA, Boyd-Wickizer, Powell SH, Burman ML. Alcohol screening questionnaires in women: a critical review. JAMA 1998;280:166-71. Medline

51.Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker WW. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996 May 25;347(9013):1438-42. Medline

52.Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 1998;22(3):573-9. Medline

53.Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999;156(11):1758-64. Medline

54.Krahenbuhl B. La "network therapy": une nouvelle approche des addictions. Med Hyg, 1994; 52:1942-5.

55.Chapuy MC, Arlot ME, Duboeuf F. Vitamin D3 and calcium to prevent hip fractures in ederly women. N Engl J Med 1992;327:1637-42. Medline

56.Cummings S, Nevitt MC, Browner WS et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995;332:767-73. Medline

57.Felson DT, Zhang Y, Hannan MT and al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-6. Medline

58.Black DM, Cummings SR, Karpf D. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41. Medline

59.Cummings S, Nevitt MC, Browner WS et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995;332:767-73. Medline

60.Dargent-Molina P, Favier F, Grandjean H et al. Fall-related factors and the risk of hip-fracture: the EPIDOS prospective study. Lancet 1996;348:145-9. Medline

61.Felson DT, Zhang Y, Hannan MT et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-6. Medline

62.Lufkin EG, Wahner HW, O'Fallon WM et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117(1):1-9. Medline

64.McNagny SE. Prescribing hormone replacement therapy for menopausal symptoms. Ann Intern Med 1999;131:605-16. Medline

65.Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13. Medline

66.Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13. Medline

67.Hu FB, Stampfer MJ, Manson JE, Grodstein F, Colditz GA, Speizer FE, Willett WC. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med 2000;343:530-7. Medline

68.Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19(1):61-109. Medline

69.Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin interventions (PEPI) Trial. The Writing Group for the PEPI trial. JAMA 1995;273:199-208. Medline

70.Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative group on hormonal factors in breast cancer. Lancet 1997;350:1047-59. Medline

71.Chapuy MC, Arlot ME, Duboeuf F. Vitamin D3 and calcium to prevent hip fractures in ederly women. N Engl J Med 1992;327:1637-42. Medline

72.Black DM, Cummings SR, Karpf D. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41. Medline

73.Ettinger B, Black DM, Mitlack BH et al. Reduction of vertebral fracture risk in postmenauposal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45. Medline

74.Lao Tseu. De la probabilité d'être gouverné par des gérontes débiles. Le Grand Rouleau -1454.

75.Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. JAMA 1998;280:1777-82. Medline

76.Bibliomed. Prise en charge des patients déments. 1999;134 Référence .

77.Risks and benefits for intracranial aneurysms in first-degree relatives of patients with sporadic subarachnoid hemorrage. The Magnetic Resonance Angiography in Relatives of Patients with Subarachnoid Hemorrhage Study Group. N Engl J Med 1999;341:1344-50. Medline

78.Crawley F, Clifton A, Brown MM. Should we screen for familial intracranial aneurysm? Stroke 1999 Feb;30(2):312-6. Medline

78 a. The Multicentre Aneurysm Screening Study Group. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet 2002;360:1531-9.Medline

79.Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med, 1998;339:364-9. Medline

80.Strom BL, Abrutyn E, Berlin JA et al. Dental and cardiac risk factors for infective endocarditis. A population-based, case-control study. Ann Intern Med 1998;129:761-69. Medline>

81.Mulley AG, Barry MJ. Controversy in managing patients with prostate cancer. Banish dogma, get more data. BMJ 1998;316: 1919-20. Medline

82.ANDEM. Traitement du cancer localisé de la prostate. Recommandations et références médicales 1995, T1, 125-51. Conc Med 1996;118:547-52 et 835-40. Référence

83.Volk RJ, Cass AR, Spann SJ. A randomized controlled trial of shared decision making for prostate cancer screening. Arch Fam Med 1999 Jul-Aug;8(4):333-40. Medline

84.Wolf AM, Philbrick JT, Schorling JB. Predictors of interest in prostate-specific antigen screening and the impact of informed consent: what should we tell our patients? Am J Med 1997 Oct;103(4):308-14. Medline

85.Adolfsson J and Carstensen J. Natural course of clinically localized prostate adenocarcinoma in men less than 70 years old. J Urol 1991;146:96-98. Medline

86.Adolfsson J. Deferred therapy in well and moderately differentiated prostate cancer. Acta Oncol 1991;30(2):225-6. Medline

87.Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992;267(16):2191-6. Medline

88.Lerner SP, Seale-Hawkins C, Carlton CE Jr, Scardino PT. The risk of dying of prostate cancer in patients with clinically localized disease. J Urol 1991;146(4):1040-5. Medline

89.Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997;277(6):467-71. Medline

90.Shroder FH, Damhuis RA, Kirkels WJ, De Koning HJ, Kranse R, Nus HG, Blijenberg BG. European randomized study of screening for prostate cancer - the Rotterdam pilot studies. Int J Cancer 1996;65(2):145-51. Medline

91.Feneley MR, Walsh PC. Incontinence after radical prostatectomy. Lancet 1999;353:2091-2. Medline

92.Savage P and al. British urological surgery practice : 1. Prostate cancer. Br J Urol 1997;79:749-55. Medline

93.Yan Y, Carvalhal GF, Catalona WJ, Young JD. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 2000;88(5):1122-30. Medline

93bis .Holmberg L, Bill-Alexon A, Helgesen F et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cance. NEJM 2002;347:781-9. Medline

93ter .de Koning HJ, Auvinen A, Berenguer Sanchez A etal. Large scale randomized prostate cancer screening trials. Int J Cancer 2002;97:237-44. Medline

94.Rouiller D. Nouveaux critères diagnostiques et classification du diabète sucré. Med Hyg 1999;57: 1284-8

95.BMI : body mass index = poids/taille2 ; normal 21-25; typiquement pour un homme de 180 cm et 75 kg: BMI = 23. 96.Peters AL, Davidson MB, Schriger DL, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus : an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. JAMA 1996;276:1246-52. Medline

97.Nikolic J, Vadas L, Unger P et Krähenbühl B. La CDT, nouveau marqueur de la consommation d'alcool, est-elle un détecteur de l'alcoolisme? Med Hyg 1994;52:1938-41.

98.Auvinen A, Tammela T, Stenman UH, Uusi-Erkkila I, Leinonen J, Schroder FH, Hakama M. Screening for prostate cancer using serum prostate-specific antigen : a randomized, population-based pilot study in Finland. Br J Cancer 1996 Aug;74(4):568-72. Medline

99.Adams PC. Population screening for hemochromatosis. Hepatology 1999;29:1324-7. Medline>

100.Balan. Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients Gastroenterology 1994;107:453-9 Medline

101.El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in sibling and children of affected patients. A cost-effectiveness analysis. Ann Intern Med 2000;132:261-9. Medline

102.Mark DB, Shaw L, Harrell FE Jr, Hlatky MA, Lee KL, Bengtson JR, McCants CB, Califf RM, Pryor DB. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med 1991;325(12):849-53. Medline

103.Goraya TY, Jacobsen SJ, Pellikka PA, Miller TD, Khan A, Weston SA, Gersh BJ, Roger VL. Prognostic value of treadmill exercise testing in elderly persons. Ann Intern Med 2000;132(11):862-70. Medline

104.Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999;354(9173):99-105. Medline

105.Landis SH, Murray T, Bolden S et al. Cancer statistics,1999. CA Cancer J Clin 1999;49:8-31. Medline

106.Rex DK, Johnson DA, Lieberman DA et al. Colorectal cancer prevention 2000 : screening recommendations of the American College of Gastroenterolgy. Am J Gastroenterol 2000;95:868-77. Medline>

107.Boland CR, Sinicrope FA, Brenner DE et al. Colorectal cancer prevention and treatment. Gastroenterology 2000;118:S115-28. Medline

108.Helm JF, Sandler RS. Colorectal cancer screening. Med Clin N Am 1999;83:1403-22. Medline

109.Bond JH. Screening guidelines for colorectal cancer. Am J Med 1999;106:7S-10S. Medline

110.Selby JV, Friedman GD, Quesenberry CP Jr et al. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Eng J Med 1992;326:653-57. Medline

111.Newcomb PA, Norfleet RG, Storer BE et al. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992;84:1572-75. Medline

112.Winawer SJ, Zauber AG, Ho MN et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polypectomy Study Workgroup. N Eng J Med 1993¨;329:1977-81. Medline

113.Rex DK, Johnson DA, Lieberman DA et al. Colorectal cancer prevention 2000 : screening recommendations of the American College of Gastroenterology. Am J Gastro 2000;95:868-77. Medline

114.Lieberman DA, Weiss DG, Bond JH. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000;343:162-8. Medline

115.Rex DK, Rahmani EY, Haseman JH et al. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology 1997;112:17-23. Medline

116.Nelson RL, Persky V, Turyk M. Time trends in distal colorectal cancer subsite location related to age and how it affects choice of screening modality. J Surg Oncol 1998;69:235-38. Medline

117.Kee F, Wilson RH, Gilliland R et al. Changing site distribution of colorectal cancer. BMJ 1992;305:158-62. Medline

118.Mamazza J, Gordon PH. The changing distribution of large intestinal cancer. Dis Colon Rectum 1982;25:558-62. Medline

119.Waye JD, Lewis BS, Yessayan S. Colonoscopy : a prospective report of complications. J Clin Gastroenterol 1992;15:347-51. Medline

120.Zubarik R, Fleischer DE, Mastropietro C et al. Prospective analysis of complication 30 days after outpatient colonoscopy. Gastrointest Endosc 1999;50:322-8. Medline

121.Dominitz JA, Provenzale D. Patients preferences and quality of life associated with colorectal cancer screening. Am J Gastroenterol 1997;92:2171-8. Medline

122.Vernon SW. Participation in colorectal cancer screening : a review. J Natl Cancer Inst 1997;89:1406-22. Medline 123.Rex DK, Cummings OW, Helper DJ et al. 5-year incidence of adenomas after negative colonoscopy asymptomatics average-risk persons. Gastroenterology 1996;111:1178-81. Medline

124.Selby JV, Friedman GD, Quesenberry CP Jr et al. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Eng J Med 1992;326:653-57. Medline

126.Rex DK, Johnson DA, Lieberman DA et al. Colorectal cancer prevention 2000 : screening recommendations of the American College of Gastroenterology. Am J Gastro 2000;95:868-77. Medline

127.Lieberman DA. Cost-effectiveness model for colon cancer screening. Gastroenterology 1995;109:1781-90. Medline

128.Provenzale D, Homan RK, Oddone EZ. Screening colonoscopy in average risk individuals is cost-effective compared with other practices. Am J Gastroenterol 1999942682 (abstract)

129.Rex DK, Johnson DA, Lieberman DA et al. Colorectal cancer prevention 2000 : screening recommendations of the American College of Gastroenterology. Am J Gastro 2000;95:868-77. Medline

130.Rex DK, Johnson DA, Lieberman DA et al. Colorectal cancer prevention 2000 : screening recommendations of the American College of Gastroenterology. Am J Gastro 2000;95:868-77. Medline

131.Rex DK. Colonoscopy : a review of its yield for cancers and adenomas by indication. Am J Gastroenterol,1995;90:353-65. Medline>

132.Rex DK, Johnson DA, Lieberman DA et al. Colorectal cancer prevention 2000 : screening recommendations of the American College of Gastroenterology. Am J Gastro 2000;95:868-77. Medline

133.Selby JV, Friedman GD, Quesenberry CP Jr et al. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Eng J Med 1992;326:653-57.Medline

134.Newcomb PA, Norfleet RG, Storer BE et al. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992;84:1572-75. Medline

135.Stewart BT, Keck JO, Duncan AV et al. Difficult or incomplete flexible sigmoidoscopy : implications for a screening programme. Aus N Z J Surg 1999;69:19-21. Medline

136.Rex DK, Lehman GA, Ulbright TM et al. The yield of a second screening flexible sigmoidoscopy in average-risk persons after one negative examination. Gastroenterology 1994;106:593-5. Medline

137.Kewenter J, Brevinge H, Engaras B et al. The yield of flexible sigmoidoscopy and double contrast barium enema in the diagnosis of neoplasms in the large bowel in patients with a positive Hemoccult test. Endoscopy 1995; 27:159-63. Medline

138.Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Eng J Med 1993;328:1365-71. Medline

139.Kronborg O, Fenger C, Olsen J et al. Randomized study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71. Medline

140.Hardcastle JD, Chamberlain JO, Robinson MH et al. Randomized controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-77. Medline

141.Delco F, Sonnenberg A. Limitations of the faecal occult blood test in screening for colorectal cancer. Ital J Gastroenterol Hepatol 1999;31:119-26. Medline

142.Ahlquist DA, Wieand HS, Moertel CG et al. Accuracy of fecal occult blood test screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 1993;269:1262-7. Medline

143.Lieberman DA, Smith FW. Screening for colon malignancy with colonoscopy. Am J Gastroenterol 1991;86:946-51. Medline

144.Rex DK, Rahmani EY, Haseman JH et al. Relative sensitivity for colonoscopy and barium enema for detection of colorectal cancer in general practice. Gastroenterology 1997;112:17-23. Medline

145.Schrock TR. Colonoscopy versus barium enema in the diagnosis of colorectal cancer and polyps. Gastrointestinal Endosc Clin N AM 1993;3:585-610

146.Hara AK, Johnson CD, Reed JE et al. Detection of colorectal polyps with CT colograpy : initial assessment of sensitivity and specificity. Radiology 1997;205:59-65. Medline 147.Rex DK, Vining D, Kopecky KK. An initial experience with screening for colon polyps using spiral CT with and without CT colograpy (virtual colonoscopy). Gastrointestinal Endosc 1999;50:309-13. Medline

148.Sonnenberg A, Delco F, Bauerfeind P. Is virtual colonoscopy a cost-effective option to screen for colorectal cancer ? A J Gastroenterol 1999;94:2268-74. Medline

149.Rex DK, Johnson DA, Lieberman DA et al. Colorectal cancer prevention 2000 : screening recommendations of the American College of Gastroenterology. Am J Gastro 2000;95:868-77. Medline

150.Boland CR, Sinicrope FA, Brenner DE et al. Colorectal cancer prevention and treatment. Gastroenterology 2000;118:S115-28. Medline

151.Zauber AG, Winawer SJ. Initial management and follow-up surveillance of patients with colorectal adenomas. Gastroenterol Clin North Am 1997;26:85-101. Medline

152.Hoff G, Sauar J, Hofstad B, Vatn MH. The Norwegian guidelines for surveillance after polypectomy : 10-year intervals. Scand J Gastroenterol 1996;31:834-6. Medline

153.Anwar S, White J, Hall C et al. Sporadic colorectal polyps : management options and guidelines. Scan J Gastroenterol 1999;34:4-11. Medline

154.Simmang CL, Senatore P. Practice parameters for detection of colorectal neoplasms. The Standards Committee, The American Society of Colon and Rectal Surgeons. Dis Col Rectum 1999;42:1123-9. Medline

155.Lydick E, Cook K, Turpin J, Melton M, Stine R, Byrnes C. Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care 1998 Jan;4(1):37-48. Medline

156.van den Hoogen PC, Feskens EJ, Nagelkerke NJ et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 2000;342:1-8. Medline

157.Sytkowski PA, D'Agostino RB, Belanger AJ et al. Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 1996;93:697-703. Medline

158.Hebert PR, Fiebach N, Eberlein KA et al. The community-based randomized trials of pharmacologic treatment of mild-to-moderate hypertension. Am J Epidemiol 1988;127:581-90. Medline

159.Insua JT, Sacks HS, Lau TS et al. Drug treatment of hypertension in the elderly : a meta-analysis. Ann Intern Med 1994;121:355-62. Medline

160.Hebert PR, Moser M, Mayer J et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993;153:578-81. Medline

161.Hebert PR, Moser M, Mayer J et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993;153:578-81. Medline

162.Hebert PR, Fiebach N, Eberlein KA et al. The community-based randomized trials of pharmacologic treatment of mild-to-moderate hypertension. Am J Epidemiol 1988;127:581-90. Medline

163.http://www.hbroussais.fr/cgi-bin/fram.p

164.1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertension 1999;17:151-83. Medline

165.Stamler R, Stamler J, Grimm R et al. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial - the Hypertension Control Program. JAMA 1987; 257:1484-91. Medline

166.Stampfer MJ, Hu FB, Manson JE et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000;343:16-22. Medline

167.Société Suisse de cardiologie. Guidelines pour l'indication au traitement du facteur de risques cardiovasculaires lipides. Bull Med Suisses 2000;81:2144-9

168.Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7. Medline

169.Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels : results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22. Medline

170.LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease : a meta-analysis of randomized controlled trials. JAMA 1999;282(24):2340-6. Medline

171.Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease : the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9. Medline

172.Calcul du risque cardio-vasculaire et cérébral selon équation de Framingham Internet

173.Laurier D, Nguyen PC, Cazelles B, Segond P. Estimation of CHD risk in a French working population using a modified Framingham model. The PCV-METRA Group. J Clin Epidemiol 1994; 47(12):1353-64. Medline

174.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 Sep 12;352(9131):837-53. Medline

175.Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342:1266-71. Medline

176 .Regazzoni S, Luzuy F, Boehlen F, Dimitrova Y, de Moerloose P. Substitution hormonale et thromboses: leçons de ces cinq dernières années. Med Hyg 2002;60:176-9.. article M+H

177 Risque thrombo-embolique et substitution hormonale (tirée de 176)
Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996 ; 348 : 983-7.Medline

Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996 ; 348 : 977-80.Medline

Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996 ; 348 : 981-3.Medline

Pérez Gutthann S, Garcia Rodriguez L, Castellsague J, Duque A. Hormone replacement therapy and risk of venous thromboembolism : Population based case-control study. BMJ 1997 ; 314 : 796-800. Medline test

180 WHI. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.JAMA. 2002 Jul 17;288(3):321-33. Medline